Omnes Capital's investments

Sector 
Industry
Entry Date 
2017
Business 
Co-Investment

World leader in the design, engineering and production of high-end audio mixing consoles for professional end-users
Headquartered in the United-Kingdom, the company designs and manufactures an expanding range of audio mixing consoles and ancillary products for professional end-users across a variety of applications. With more than a hundred of employees, it has an outstanding reputation for innovation, best-in-class performance and reliability in demanding live productions.
Sector 
Industry
Entry Date 
2017
Business 
Co-Investment

European market leader for premium temporary space solutions
Headquartered in Germany, the company provides temporary and modular building solutions for the industrial sector, special events and large missions requiring rapid deployment systems.
Sector 
Pharma
Entry Date 
2017
Business 
Venture Capital

Octimet

Development of a clinically de-risked MET kinase inhibitor for the treatment of cancers

Founded in 2016, Octimet Oncology N.V. (Belgium) is a new company (spin-off from Johnson & Johnson) that acts as a translational accelerator, focusing on creating value for investors and patients by providing rapid clinical proof of concept for cancer therapies through innovative clinical development strategies and patient centered biomarker approaches. The current focus is on its clinical stage asset OMO-1, a highly selective small molecule MET inhibitor that will be developed with specific biomarkers, whilst an additional late pre-clinical stage oncology asset 0MO-2 will also enter the portfolio.

Sector 
Business services
Entry Date 
2016
Business 
Co-Investment

Global leading software editor for the simulation of sheet metal forming in the automotive industry
Headquartered in Switzerland, the company is the reference software editor for the simulation of sheet metal forming processes to the automotive industry.
Sector 
Pharma
Entry Date 
2016
Business 
Co-Investment

French pharmaceutical company specialized in complex generics
Headquartered in France with a global footprint, the company is specialised in the manufacturing and distribution of products with challenging formulations.
Sector 
Web
Entry Date 
2016
Business 
Co-Investment

Global provider of web content management
Headquartered in Denmark , the company is a global software company with a strong footprint in the web content and customer experience management.
Sector 
Consumer goods
Entry Date 
2014
Business 
Co-Investment

Global leader in the market of high-end home audio
Headquartered in the United Sates, the company is one of the global leader on high-end home audio.
Sector 
Business services
Entry Date 
2014
Business 
Co-Investment

Leading environmental service provider in the Nordics
Headquartered in Finland, the company is a leading provider of business services in Sweden and Finland. With more than 650 employees and 33 facilities, the group provides three complementary services: industrial cleaning, demolition and waste treatment.
Sector 
Infrastructure
Entry Date 
2014
Business 
Renewable Energy

Villages Nature

13 MW geothermal heating network
The project is to build and operate a geothermal power plant that will supply a heating network providing hot water and heating to Euro Disney and a Pierre et Vacances holiday park. The plan is for the heating network to add further customers in the future (business parks, shopping centres). This is the Renewable Energy team’s first heating network. Omnes Capital acquired a 51% stake in this installation.
Sector 
Pharma
Entry Date 
2013
Business 
Venture Capital

Opsona Therapeutics

Novel therapeutic approaches to key targets of the innate immune system
Opsona is a leading immunology drug development company, focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of major human diseases, including autoimmune and inflammatory diseases, transplant rejection, cancer, diabetes, Alzheimer's disease and atherosclerosis. The company was founded in 2004 by three world-renowned immunologists at Trinity College in Dublin.

Pages

NewsRoom
Press release
28 November 2017
OMNES UNVEILS ITS INVESTMENT STRATEGY FOR DEEP-TECH B2B START-UPS TO SUPPORT TECHNOLOGICAL BREAKTHROUGHS

OMNES UNVEILS ITS INVESTMENT STRATEGY FOR DEEP-TECH B2B START-UPS TO SUPPORT TECHNOLOGICAL BREAKTHROUGHS
Press release
23 October 2017
Appointments within Omnes Capital:
Omnes Capital has promoted two Principals and three Associates and is welcoming one new Associate, a Director of Operations and a new Head of Human Resources.

Appointments within Omnes Capital: Omnes Capital has promoted two Principals and three Associates and is welcoming one new Associate, a Director of Operations and a new Head of Human Resources.
Publication
Omnes Newsletter no 32: Nicolas Ricart, CEO Batiweb Group
Press release
14 September 2017
Omnes Capital invests in Aero Negoce International (ANI) through an Owner Buy-Out (OBO)
Omnes Capital invests in Aero Negoce International (ANI) through an Owner Buy-Out (OBO)
Press release
26 July 2017
Omnes Capital completes primary LBO of the Geoxia Group's brands in the Nouvelle Aquitaine region (Maisons Clairlande, Les Demeures de la Côte d’Argent, Rouquié Constructions)
Omnes Capital completes primary LBO of the Geoxia Group's brands in the Nouvelle Aquitaine region (Maisons Clairlande, Les Demeures de la Côte d’Argent, Rouquié Constructions)
Press release
29 June 2017
Omnes Capital and the Evolution incubator conclude partnership through La Foncière des Lunes to develop regional projects with high environmental standards
Omnes Capital and the Evolution incubator conclude partnership through La Foncière des Lunes to develop regional projects with high environmental standards

Pages